Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05351593Phase 1Recruiting

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Role: lead

NCT04656431Phase 1Recruiting

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

Role: lead

NCT01542918Phase 1Completed

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Role: lead

All 3 trials loaded